Tempus AI, Inc. (TEM)

Tempus is a healthcare technology company that applies artificial intelligence, including generative and agentic AI, to create what it calls Intelligent Diagnostics. These are laboratory tests whose results are connected to a patient's own clinical data, so that results are more accurate, tailored and personal and can guide therapy selection, clinical trial matching and treatment decisions. The company built the Tempus Platform, which combines a technology platform that frees healthcare data from silos with an operating system that makes the data useful. Through it, Tempus has assembled what it considers one of the largest libraries of clinical and molecular oncology data in the world.

Products are organized into two product lines. Diagnostics comprises the Oncology and Hereditary testing businesses, among others, and uses the company's laboratories to provide next generation sequencing (NGS), PCR profiling and other anatomic and molecular pathology testing. Data and applications includes Insights, Trials, Next and Algos, among others. Insights licenses de-identified libraries of linked clinical, molecular and imaging data, along with analytic and cloud-and-compute tools. Trials uses the company's oncology physician network to support clinical trials for pharmaceutical companies seeking hard-to-find and underserved patient populations. Next is an AI platform that applies an "intelligent layer" to routinely generated data to identify care gaps for oncology and cardiology patients. Algos develops algorithmic diagnostics, with oncology offerings that include the TO, HRD, DPYD and Tempus Purist Algos. The company says the two product lines enhance each other and create network effects.

Customers include healthcare providers, life sciences companies (pharmaceutical and biotechnology), researchers and other third parties. Its products and services are ordered by more than 5,000 healthcare institution sites, and the platform is being deployed at scale in oncology in the United States, with other disease areas following. The platform spans oncology, neurology and cardiology, and collects multimodal data including NGS, pathology slides, radiology images and other laboratory tests, often linked to electronic health record data on phenotype, therapy and outcomes.

Operationally, Tempus runs its own laboratories and describes itself as one of the largest sequencers of cancer patients in the United States. Its platform includes proprietary software and data pipelines with more than 700 unique data connections to healthcare institutions, many supplying data in near real time. Tempus receives data as a covered entity, for example when providing NGS services, or as a business associate, for example for clinical trial matching and data de-identification and structuring. It also has a limited number of paid license agreements to acquire de-identified data directly and in some cases covers the direct costs of technical integrations. The text provided does not identify specific suppliers, competitors or headquarters location.